

Homebased Medication Review: evaluation of homebased medication review by community pharmacists in elderly people: a randomised controlled trial

Submission date	Recruitment status	<input type="checkbox"/> Prospectively registered
05/09/2007	No longer recruiting	<input type="checkbox"/> Protocol
Registration date	Overall study status	<input type="checkbox"/> Statistical analysis plan
05/09/2007	Completed	<input type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
17/09/2008	Other	<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr A. Faber

Contact details

SIR Institute for Pharmacy Practice and Policy

Leiden

Netherlands

2331 JE

+31 (0)71 576 6157

a.faber@stevenshof.nl

Additional identifiers

Protocol serial number

NTR1036

Study information

Scientific Title

Study objectives

An home-based medication review intervention conducted by a community pharmacists in close collaboration with the General Practitioner (GP) and patient improves the quality of pharmacotherapy in elderly patients.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Medical Ethics Board of UMC Utrecht (University Medical Centre in Utrecht) (The Netherlands) on the 7th August 2007 (ref: 07-120/E; CCMO no.: 16412.041.07).

Study design

Multicentre, randomised, placebo-controlled, parallel group trial

Primary study design

Interventional

Study type(s)

Quality of life

Health condition(s) or problem(s) studied

Home-based medication review

Interventions

A medication review will be performed by the patients pharmacist, using the medication list and GP clinical records. The medication review is evaluated and, if necessary, completed by an independent pharmacist panel. All potential drug related problems are identified and classified. The pharmacist visits the patient at home for an interview about the patient's medicines and to identify other possible drug related problems. The medication review will be completed using the information from the patient's interview. Adjustments in pharmacotherapy will be proposed and discussed with the patients GP. A treatment plan will be formulated. The GP or pharmacist will discuss the treatment plan with the patient.

Patients in the control group receive regular care.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

1. The number of drug related problems per patient
2. The number of patients achieving target levels concerning blood pressure, cholesterol and HbA1C

Outcomes will be measured at baseline ($t = 0$), and after 6 and 12 months after the intervention.

Key secondary outcome(s)

1. The number of patient being treated optimally according to clinical guidelines
2. The number of medicines per patient
3. The number unplanned hospital admissions
4. Change in mean values for HBA1C, cholesterol level and/or blood pressure
5. Quality of life
6. Satisfaction of GPs, pharmacists and patient with the intervention
7. The capability of pharmacists to perform a comprehensive medication review

Outcomes will be measured at baseline ($t = 0$), and after 6 and 12 months after the intervention.

Completion date

01/09/2009

Eligibility

Key inclusion criteria

1. Persons aged 65 years or older
2. Prescribed five or more regular medicines, including at least one cardiovascular or anti-diabetic drug

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Sex

All

Key exclusion criteria

Persons receiving repeat prescriptions solely from a specialist.

Date of first enrolment

01/09/2007

Date of final enrolment

01/09/2009

Locations

Countries of recruitment

Netherlands

Study participating centre
SIR Institute for Pharmacy Practice and Policy
Leiden
Netherlands
2331 JE

Sponsor information

Organisation
Lloyds Apotheken (The Netherlands)

ROR
<https://ror.org/04ph6g561>

Funder(s)

Funder type
Industry

Funder Name
AstraZeneca (The Netherlands)

Alternative Name(s)
AstraZeneca PLC, Pearl Therapeutics, AZ

Funding Body Type
Government organisation

Funding Body Subtype
For-profit companies (industry)

Location
United Kingdom

Funder Name
Menzis Healthcare Insurance (Menzis Zorgverzekeraar) (The Netherlands)

Funder Name
Lloyds Apotheken (The Netherlands)

Funder Name

Achmea (The Netherlands)

Funder Name

Royal Dutch Pharmaceutical Society (Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie [KNMP]) (The Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary